Dynamic dashboard

The Global AMR R&D Hub tracks 12+ billion USD in global One Health investments, clinical antibacterial products, and antibiotic R&D incentives.

To the Dynamic Dashboard

Investment Gallery

The global knowledge center for all AMR R&D activities and investments across the One Health continuum.

Go to Investment Gallery

Pipeline Gallery

Pipeline of products in clinical development and products that were recently approved.

Go to Pipeline Gallery

Incentives Gallery

What are we doing to fix the challenges hindering the development of, and access to, priority antibacterials for human health.

Go to Incentives Gallery

Guide for usage

Dynamic Dashboard Library

The Dynamic Dashboard is designed to be a resource for everyone working in the field of AMR R&D to support evidenced based decision making on where efforts and resources may be best allocated. To ensure that the information contained in the Dynamic Dashboard is reproducible, the Secretariat has developed a number of documents to ensure the transparency of our methods and data sources. This information will also assist people wanting to link to or extract and use the Dynamic Dashboard information for their own purposes.

As the Dynamic Dashboard will be evolving over time to broader geographical scope, more pathogens and to all One Health sectors, our documents will be regularly updated to ensure our data can be extracted, used and interpreted appropriately.

Go to user guide

Learn more

Categories and Definitions Investments

The definitions are intended to be applicable across the different One Health sectors.

Categories and Definitions Incentives

The aim of the presented information in the Dynamic Dashboard´s Incentive Gallery is on capturing, displaying and tracking draft and implemented initiatives, worldwide, with the potential to improve the functioning of markets – and the broader R&D ecosystem – responsible for the development and distribution of therapeutics for the treatment of priority, human, bacterial infections.

The only exception is those initiatives under category ‘06. Improving continuity of supply’. This largely pertains to old antibiotics whose patents have expired. This category has been broken into five sub-categories or challenges under which ad hoc, illustrative, examples of ways actors are addressing the challenges are captured (see below).

The exclusion criteria are to ensure – in the absence of output or impact data – the focus of our incentive capture remains on those activities with the potential to have more than a narrow, local or transient impact. We will work towards fostering a long-term, sustainable, R&D ecosystem.

The scope and definitions provided below represent this initial focus.

Categories have been developed, that represent targets for incentives or incentive strategies, along the value-chain from discovery to consumption.


  1. Incentives in Scope
  2. Supporting Definitions
  3. Exclusion Criteria
  4. Categories

1. Incentives in Scope

Any draft and implemented initiatives with the potential to improve the functioning (efficiency, productivity) of the R&D ecosystem responsible for the development and distribution of therapeutics for the treatment of priority, human, bacterial infections.

The activities could include but are not limited to:

  1. Direct financial support, through a dedicated or majority-focused financing tool/stream
  2. Dedicated initiatives, structures, organizations, networks or activities with an AMR product R&D relevant mandate (in part or full)
  3. Legislative or regulatory actions that have been put forward &/or ratified into law

2. Supporting Definitions

Push incentive (covers categories 01-04):
Input-based; push mechanisms target current work and reduce a developers cost & risk of researching and developing new drugs either by lowering the costs, decreasing the barriers to participation or by sharing the costs/risks across multiple parties.

Pull incentive (covers categories 05-09):
Output-based; rewarding the successful development of a drug by increasing or ensuring future revenue. Can be achieved through market-making (financial) tools or market-shaping (lego-regulatory policies) rewards.

R&D ecosystem:
Public and private product developers including the R&D context or facilitatory environment in which they conduct their work. Includes actors, collaborations, infrastructures, lego-regulatory frameworks, institutions and competencies.

Priority infections:
Human bacterial infections considered a current or emerging public health priority as defined by the WHO´s priority pathogen list.

3. Exclusion Criteria

Information will not be collected for incentives on:

  1. Policy proposals, discussions or draft legislations in development but not yet tabled
  2. Single or ad hoc financial awards that do not present the possibility for a sustained impact
  3. Activities that are very-narrow in their focus such as those targeting a specific/single indication, syndrome, technical challenge, product or trial
  4. Non-dedicated or majority-earmarked activities (for investments these are captured by our investment gallery)
  5. One-off or time-limited interventions (less than 5 years)
  6. Tax-based incentives
  7. Interventions specifically targeting the tuberculosis (TB) market
  8. Interventions targeting non-human or non-therapeutic product markets
  9. Sub-national (state-level) interventions

4. Categories

Our launch categories have been created to represent targets, or strategies, for incentives along the value-chain. As much as possible, these try to be mutually exclusive and encompass all incentives that may conceivably be implemented now and in the future. As with all taxonomies categorization can sometimes be an artificial exercise that will fit some incentives better than others.

1. Supporting early-stage R&D
Includes support (financial or otherwise) for research, development and translation relating to discovery and preclinical research, and Phase I clinical trials.

2. Enhancing clinical trial conduct
Includes strategies to enhance clinical trial conduct and infrastructure to improve efficiency, reduce duplication and generate better data.

3. Supporting late-stage R&D
Includes support (financial or otherwise) for the conduct of Phase II and III registration trials through to product filing.

4. Streamlining regulatory requirements
Includes the clarification, optimisation and convergence of regulatory requirements across indications and regulators to decrease the time and expense for products to reach patients.

5. Earlier & broader uptake
Includes support for new data-generation and better use of all available data so patients may benefit from newer agents more rapidly. Also includes mechanisms to cushion smaller developers in the initial post-launch phase.

6. Improving continuity of supply
Includes system, regulatory and market-making measures with the objective of fostering a sustainable and predictable market for older efficacious antibiotics (particularly for those products where there are few or no alternatives).

The five sub-categories or challenges under which illustrative examples or solutions are found are:

  1. Fostering, green, diverse, sustainable sourcing
  2. Expansion & optimisation of finished product manufacturing
  3. Securing & stabilising demand/supply continuity
  4. Mitigating & responding to short-term supply disruptions
  5. Fostering transparency & improved information usage

7. Enhancing relative market attractiveness
Includes strategies to enhance the attractiveness of the market relative to other therapeutic areas, and within the antibiotic class, by implementing regulatory, system and financial levers nationally, trans-nationally or globally.

8. Expediting sustainable global patient access
Includes measures to improve the speed of access and affordability to patients globally while ensuring appropriate stewardship.

9. Priority signaling & orientation
Includes actions to signal and reinforce the global public good nature of antibiotics and public health need for an R&D ecosystem oriented towards the development, distribution and preservation of priority antibiotics, globally.

Infectious Agents in Scope

List of infectious agents included in the Dynamic Dashboard

Currently in scope, and included in the list, are human bacteria pathogens and all infectious agents in animals relevant for AMR R&D.

Data Sources



  • Agencia Nacional de Promoción Científica y Tecnológica, Argentina
  • Ministry of Science, Technology and Productive Innovation
  • National Scientific and Technical Research Council, Argentina




  • Agency for Innovation through Science and Technology (IWT)
  • Belgian Federal Science Policy Office
  • Fund for Scientific Research
  • Research Foundation Flanders



  • Bulgarian Science Fund


  • Alberta Innovates
  • Canadian Institutes of Health Research
  • Fonds de Recherche du Québec – Nature et Technologies
  • Fonds de Recherche du Québec – Santé
  • Fonds de Recherche du Québec – Société et culture
  • Global Affairs Canada
  • International Development Research Centre
  • Michael Smith Foundation for Health Research
  • Michael Smith Health Research BC
  • Ministry of Colleges and Universities
  • Ministry of Research, Innovation and Science
  • Natural Sciences and Engineering Research Council
  • Nova Scotia Health Research Foundation
  • Public Health Agency of Canada
  • Research Manitoba
  • Saskatchewan Health Research Foundation
  • Social Sciences and Humanities Research Council


  • Agencia Nacional de Investigación y Desarrollo



  • Croatian Science Foundation


  • Research Promotion Foundation

Czech Republic


  • Danish Agency for Science and Higher Education
  • Repair Impact Fund
  • Independent Research Fund Denmark
  • Innovation Fund Denmark
  • Novo Nordisk Foundation
  • The Velux Foundations


  • Academy of Scientific Research and Technology, Egypt


European Union




  • Shota Rustaveli National Science Foundation


Global Partnerships


  • General Secretariat for Research and Technology


  • Hungarian Scientific Research Fund
  • National Research, Development and Innovation Office


  • The Icelandic Centre for Research



  • Dana Ilmu Pengetahuan Indonesia




  • Italian Medicines Agency
  • Ministero della Salute
  • Ministry of Education, Universities and Research


Republic of Korea

  • Animal And Plant Quarantine Agency, Korea
  • Centers for Disease Control & Prevention, Korea
  • Drug Development Fund, Korea
  • Korea Environmental Industry & Technology Institute
  • Evaluation Institute of Industrial Technology, Korea
  • Health Industry Development Institute, Korea
  • Institute of Marine Science & Technology Promotion, Korea
  • Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry, Korea
  • Research Institute of Bioscience and Biotechnology, Korea
  • Technology and Information Promotion Agency for SMEs, Korea
  • Nano-Convergence Foundation, Korea
  • Korean National Research Foundation
  • Rural Development Administration, Korea


  • Ministry of Education and Science
  • State Education Development Agency

The Netherlands

  • Dutch Research Council
  • Ministry of Economic Affairs and Climate Policy
  • Netherlands Enterprise Agency
  • Netherlands Organisation for Health Research and Development
  • NWO & Dutch Ministry for Health

New Zealand


  • Research Council Norway
  • Trond Mohn foundation (previously Bergen Research Foundation)
  • Western Norway Regional Health Authority


  • Foundation for Polish Science
  • Ministry of Agriculture and Rural Development
  • Ministry of Science and Higher Education
  • National Centre for Research and Development
  • National Science Center


  • Fundação para a Ciência e Tecnologia


  • Qatar Foundation


  • Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii



  • Ministry of Health
  • National Medical Research Council
  • National Research Foundation


  • Ministry of Education, Science, Research and Sport of the Slovak Republic
  • Slovak Research and Development Agency

South Africa

  • NRF SA
  • South African Medical Research Council
  • Water Research Commission


  • La Agencia Estatal de Investigación
  • Instituto de Salud Carlos III, Spain
  • Ministry of Economy, Industry and Competitiveness
  • National Institute for Agriculture and Food Research and Technology



  • Innosuisse – Swiss Innovation Agency
  • Swiss Federal Food Safety and Veterinary Office
  • Swiss Federal Office for Agriculture
  • Swiss Federal Office of Public Health
  • Swiss National Science Foundation


  • Ministry of Higher Education and Scientific Research


  • Atatürk University
  • The Scientific and Technological Research Council of Turkey

United Kingdom

United States of America

Methodology for developing the categorisation fields

Establishing the Dynamic Dashboard – Methodology for developing the categorisation fields.

Approach for presenting the pipeline of antibacterials in clinical development

Global AMR R&D Hub approach for presenting the pipeline of antibacterials in clinical

Data collection, processing, categorization and presentation

The goal of the Dynamic Dashboard is to present basic and applied research projects/investments from publicly and privately funded R&D throughout the research and innovation value chain on treatment, preventive measures, diagnostic products, surveillance, policy and interventions (such as stewardship) across all One Health sectors.


To be the global knowledge centre for all antimicrobial resistance (AMR) research and development (R&D) activities across the One Health continuum. The dashboard will support global priority setting and decision making and lead to more efficient use of international resources through the identification of gaps, overlaps and potential for cross sectoral collaboration and leveraging in AMR R&D.

Subscribe to our newsletter

You can sign up for our newsletter here. By subscribing, you automatically provide your consent for the use of your data in accordance with our privacy policy.

This field is for validation purposes and should be left unchanged.
Dynamic Dashboard